AB0498 ASSOCIATION OF METABOLIC PATHWAY-RELATED SINGLE NUCLEOTIDE POLYMORPHISMS WITH ORAL METHOTREXATE TREATMENT OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS

• Published in: Annals of the rheumatic diseases Vol. 83; no. Suppl 1; p. 1518
• Main Author: Rahman, A.
• Format: Journal Article
• Language: English
• Published: Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024; Elsevier B.V; Elsevier Limited
• Subjects: Adverse events; Best practices; Comorbidity; Creatinine; Disease-modifying Drugs (DMARDs); Hypothyroidism; Metabolic pathways; Metabolism; Methotrexate; Methylenetetrahydrofolate reductase; Nausea; Outcome measures; Patients; Polymerase chain reaction; Polymorphism; Quality of life; Restriction fragment length polymorphism; Rheumatoid arthritis; Rheumatoid factor; Rheumatology; Scientific Abstracts; Single-nucleotide polymorphism; Outcome measures; Best practices; Disease-modifying Drugs (DMARDs)

Background:Methotrexate (MTX) metabolic pathway-related single nucleotide polymorphisms (SNPs) are associated with its response, non-response, and developing adverse drug reactions (ADR), which may help in the modification of rheumatoid arthritis (RA) treatment.Objectives:To determine the associatio...